Subscribe To
XPHYF / Xphyto Announces Engagement of Consultants for Marketing and Promotional Activities
XPHYF News
By Proactive Investors
June 8, 2022
XPhyto Therapeutics says pharmaceutical manufacturing expert Dr Florian A. Sahr has joined its European operations as project management head
XPhyto Therapeutics Corp has announced that Dr Florian A. Sahr, a German-born and internationally-trained leader in drug formulation, technology trans more_horizontal
By Proactive Investors
April 4, 2022
XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year
XPhyto Therapeutics Corp has updated on the progress of its Rotigotine transdermal (TDS) patch product candidate, which is a non-ergoline dopamine ag more_horizontal
By Proactive Investors
February 22, 2022
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal
By Proactive Investors
February 22, 2022
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal
By Proactive Investors
February 22, 2022
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laborator more_horizontal
By Proactive Investors
February 8, 2022
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal
By Proactive Investors
February 8, 2022
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal
By Proactive Investors
February 8, 2022
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in comin more_horizontal
